BELL Stock Overview
Develops and commercialize oxygen related medical device products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Belluscura plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.14 |
| 52 Week High | UK£0.52 |
| 52 Week Low | UK£0.07 |
| Beta | 1.12 |
| 11 Month Change | -3.33% |
| 3 Month Change | 87.10% |
| 1 Year Change | -55.38% |
| 33 Year Change | -77.34% |
| 5 Year Change | n/a |
| Change since IPO | -72.64% |
Recent News & Updates
Shareholder Returns
| BELL | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -1.2% |
| 1Y | -55.4% | -3.6% | 4.5% |
Return vs Industry: BELL underperformed the UK Medical Equipment industry which returned -3.6% over the past year.
Return vs Market: BELL underperformed the UK Market which returned 4.4% over the past year.
Price Volatility
| BELL volatility | |
|---|---|
| BELL Average Weekly Movement | 15.0% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BELL's share price has been volatile over the past 3 months.
Volatility Over Time: BELL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 35 | Bob Rauker | www.belluscura.com |
Belluscura plc develops and commercialize oxygen related medical device products in the United States. The company offers X-PLOR and DISCOV-R, a modular portable oxygen concentrator; and related accessories. Belluscura plc was incorporated in 2015 and is based in London, the United Kingdom.
Belluscura plc Fundamentals Summary
| BELL fundamental statistics | |
|---|---|
| Market cap | UK£24.42m |
| Earnings (TTM) | -UK£14.34m |
| Revenue (TTM) | UK£639.31k |
38.2x
P/S Ratio-1.7x
P/E RatioIs BELL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BELL income statement (TTM) | |
|---|---|
| Revenue | US$825.41k |
| Cost of Revenue | US$5.03m |
| Gross Profit | -US$4.20m |
| Other Expenses | US$14.31m |
| Earnings | -US$18.52m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | -509.22% |
| Net Profit Margin | -2,243.45% |
| Debt/Equity Ratio | 0% |
How did BELL perform over the long term?
See historical performance and comparison